Overview

The Evira Study: Additional Support During Anti-Obesity Treatment

Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with anti-obesity medication in adolescents with obesity. The main question it aims to answer is: \- Can a combination of a digi-physical treatment tool and anti-obesity medication improve treatment outcomes for patients with obesity compared to patients treated with anti-obesity medications alone? This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.
Phase:
NA
Details
Lead Sponsor:
Karolinska Institutet
Collaborator:
Evira AB
Treatments:
Liraglutide
semaglutide